METHOD OF PREDICTING ADMINISTRATING SAFETY OF OSELTAMIVIR PHOSPHATE MEDICINE

• Main Authors: SUN, YING, GU, XIAOCHENG, WEI, LIPING, YU, QUAN, ZHANG, WUXUE, HE, QUANYUAN, LUO, JINGCHU, LI, CHUANYUN, YE, ZHIQIANG, ZHENG, XIAOFENG
• Format: Patent
• Language: Chinese; English; French
• Published: 18.10.2007
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

A method of predicting administrating safety of Oseltamivir Phosphate medicine is as follows: detecting the genotype of Arg41Gln single nucleotide polymorphic site of HsNEU2 protein gene in the testee's sialidase protein family for predicting testee's sensitivity to the side effect of Tamiflu medicine. Oseltamivir Phosphate medicine will produce side effect to individuals with SNP site genotype of A/A. Oseltamivir Phosphate medicine has certain risk to those with SNP site genotype of A/G. And Oseltamivir Phosphate medicine is safe to those with SNP site genotype of G/G. The present invention also provides one kind of convenient reagent kit for the said safety prediction. Owing to the possibility of Oseltamivir Phosphate medicine to result in serious side effects, such as some cutaneous and nerval symptoms, the detection of individual genotype is necessary before the use of Tamiflu medicine against influenza in Asia where the probability of SNP mutant is close to 10%. La présente invention concerne un procédé